Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study.
bias
chronic pain
oxycodone
sex
tapentadol
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
02 Oct 2022
02 Oct 2022
Historique:
received:
28
07
2022
revised:
16
09
2022
accepted:
30
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Despite the large body of research on sex differences in pain, there is a lack of translation to real-world pain management. Our aim was to analyse the sex differences in the analgesic response to oxycodone/naloxone (OXN) and tapentadol (TAP), in comparison with other opioids (OPO) commonly prescribed for chronic non-cancer pain (CNCP). An observational and cross-sectional study was conducted on ambulatory CNCP patients (n = 571). Sociodemographic, clinical (pain intensity, relief, and quality of life), safety (adverse events (AEs), adverse drug reactions), hospital frequentations and pharmacological (morphine equivalent daily dose (MEDD)) variables were collected. Multiple linear regressions were carried out to assess the association between sex and outcomes. Sex differences were observed, with lower female tolerability and higher hospital frequentation, especially in the OXN group (OR AEs report = 2.8 [1.8−4.4], p < 0.001). Here, females showed higher hospital use (23% hospital admission, 30% prescription change, p < 0.05), requiring a higher MEDD (127 ± 103 mg/day, p < 0.05), compared to OXN men. Regardless of the opioid group, CNCP women were significantly older than men (three years), with significantly higher benzodiazepine use (OR = 1.6 [1.1−2.3]), more constipation (OR = 1.34 [0.93−1.90]) and headache (OR = 1.45 [0.99−2.13]) AEs, than men who were more likely to refer sexual dysfunction (OR = 2.77 [1.53−5.01]), and loss of libido (OR = 1.93 [1.22−3.04]). Sex-differences were found related to poorer female drug tolerability and higher hospital resources, even worst in OXN female users. Other differences related to older female ages and benzodiazepine prescription, need to be further analysed from a gender perspective.
Identifiants
pubmed: 36289731
pii: biomedicines10102468
doi: 10.3390/biomedicines10102468
pmc: PMC9598624
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Heart Lung. 1995 Nov-Dec;24(6):427-35
pubmed: 8582818
Ann Ist Super Sanita. 2016 Apr-Jun;52(2):184-9
pubmed: 27364392
Pain Med. 2015 Oct;16(10):1943-54
pubmed: 26332513
Pharmacol Res. 2019 Oct;148:104447
pubmed: 31499196
Eur Psychiatry. 2015 Sep;30(6):778-88
pubmed: 26052073
J Pain. 2008 Dec;9(12):1144-54
pubmed: 18708300
Expert Opin Investig Drugs. 2011 Apr;20(4):427-39
pubmed: 21395483
Pain. 2016 Aug;157(8):1618-25
pubmed: 26934512
BMJ Open. 2013 May 03;3(5):
pubmed: 23645921
Biol Sex Differ. 2021 May 3;12(1):34
pubmed: 33941259
Nat Rev Dis Primers. 2017 Feb 16;3:17002
pubmed: 28205574
Pain Med. 2014 May;15(5):791-806
pubmed: 24517173
Lancet Neurol. 2010 Aug;9(8):807-19
pubmed: 20650402
Pain Res Manag. 2018 Feb 25;2018:6358624
pubmed: 29682130
Clin J Pain. 2003 May-Jun;19(3):175-86
pubmed: 12792556
Pain Res Manag. 2003 Spring;8 Suppl A:3A-28A
pubmed: 14685304
Maturitas. 2019 Nov;129:76-84
pubmed: 31547918
J Pain Res. 2019 May 16;12:1569-1576
pubmed: 31190968
Sci Rep. 2022 Jun 16;12(1):10126
pubmed: 35710811
Gend Med. 2005 Sep;2(3):137-45
pubmed: 16290886
Farm Hosp. 2020 Apr 14;44(3):109-113
pubmed: 32452310
BMC Pharmacol Toxicol. 2013 Aug 01;14:39
pubmed: 23915423
Emerg Med J. 2001 May;18(3):205-7
pubmed: 11354213
Curr Med Res Opin. 2013 Jun;29(6):661-6
pubmed: 23540512
Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):439-448
pubmed: 30549211
Ann Emerg Med. 2001 Dec;38(6):639-43
pubmed: 11719742
Annu Rev Neurosci. 2009;32:1-32
pubmed: 19400724
Pain Physician. 2013 Nov-Dec;16(6):E685-704
pubmed: 24284847
Clin J Pain. 2020 Jun;36(6):420-429
pubmed: 32149782
Pain Med. 2013 Oct;14(10):1461-7
pubmed: 23742116
Am Heart J. 2010 Apr;159(4):677-683.e1
pubmed: 20362729
Front Psychiatry. 2019 May 28;10:314
pubmed: 31214054
Scand J Psychol. 2019 Aug;60(4):338-347
pubmed: 31124165
J Affect Disord. 2015 Mar 15;174:303-9
pubmed: 25532077
Acta Anaesthesiol Scand. 2019 Feb;63(2):248-258
pubmed: 30109708
Ther Adv Drug Saf. 2018 Apr;9(4):197-205
pubmed: 29623185
Acta Obstet Gynecol Scand. 2003 Jul;82(7):649-53
pubmed: 12790847
Pharmacogenomics J. 2020 Apr;20(2):320-328
pubmed: 31745220
Prog Brain Res. 2010;186:141-57
pubmed: 21094890
Palliat Med. 2011 Jul;25(5):504-15
pubmed: 21708857
Pharmgenomics Pers Med. 2020 Mar 13;13:71-79
pubmed: 32214840
Pharmacol Res. 2016 Jun;108:31-38
pubmed: 27107788
J Clin Med. 2021 Oct 18;10(20):
pubmed: 34682891
Gac Sanit. 2004 May;18 Suppl 1:118-25
pubmed: 15171867
Expert Opin Drug Saf. 2021 Jan;20(1):69-79
pubmed: 33191796
J Orofac Pain. 2000 Summer;14(3):169-84; discussion 184-95
pubmed: 11203754
Best Pract Res Clin Gastroenterol. 2011 Feb;25(1):127-40
pubmed: 21382584
Br J Pain. 2016 Nov;10(4):217-221
pubmed: 27867511
Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:56-65
pubmed: 26149383
Klin Khir. 2014 May;(5):52-5
pubmed: 25675769
BMJ Open. 2021 Jun 30;11(6):e044157
pubmed: 34193479
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008921
pubmed: 22258992
Int J Environ Res Public Health. 2020 Jun 01;17(11):
pubmed: 32492925